4 Stocks to Buy Before the End of 2026!

4 Stocks to Buy Before the End of 2026!

Analisado Ver no YouTube Solicitado Em
Retorno do vídeo
-13,16%
Chamadas
3
Compra / Venda
3 0
Publicado

Recomendações

Entrada é o preço de fechamento do ativo na data de publicação. Atual é o último fechamento registrado.

  1. 01 KRYS NASDAQ COMPRAR +1,20%
    Entrada $305,23 14 nov 2026
    Atual $308,89 20 nov 2026
    Resultado +$3,66
    vs. índice +9,8% SPY −8,6% no mesmo período
    Contexto da transcrição original
    …. So, fascinating business, very much in the early stages of its growth. It has its one very profitable key flagship product, but they are rapidly expanding into other rare disease areas. It's a profitable business. It's a high margin one. Might be one to at least put on your watch list, if not your buy list, if you're interested in putting cash to work in biotech stocks. >> Very interesting name. I mean, the biotech segment of the market is one where it's either you're going to be very very successful or or it's a name where you probably won't hear about it a couple of years a couple of years down the line…

    Might be one to at least put on your watch list, if not your buy list, if you're interested in putting cash to work in biotech stocks.

    Contexto extraído por IA It's a profitable business. It's a high margin one. Might be one to at least put on your watch list, if not your buy list, if you're interested in putting cash to work in biotech stocks. >> Very interesting name. I mean, the biotech segment of the market is one where it's either you're going to be very very successful or or it's a name where you probably won't hear about it a couple of years a couple of years down the line, but from what I I've just heard and and seen seems like a a pretty good company has also performed quite well uh this year and and over the past uh 12 months. So, pretty pretty good.

  2. 02 BLLN NASDAQ COMPRAR -14,48%
    Entrada $105,15 14 nov 2026
    Atual $89,92 20 nov 2026
    Resultado −$15,23
    vs. índice −5,9% SPY −8,6% no mesmo período
    Contexto da transcrição original
    …s a long way for billion to want u to run and I think this is certainly a business to at least put on your watch list before the end of 2026. It's certainly a very cool name. >> Billion to one. It's very catchy. >> Yeah. >> Okay, everyone. That's [music] four stocks that Neil and I would consider buying before the end of 2026. For Neil, we [music] had Rocket Lab and Nvidia. I talked about two healthcare names, Crystal Biotech and Billion. [music] Let us know your thoughts in the comments. What stocks are on your buy lists before the end of the year? Let us know. Hit the like and subscribe buttons and we will see you in the next video.

    That's [music] four stocks that Neil and I would consider buying before the end of 2026. For Neil, we [music] had Rocket Lab and Nvidia. I talked about two healthcare names, Crystal Biotech and Billion.

    Contexto extraído por IA Okay, everyone. That's [music] four stocks that Neil and I would consider buying before the end of 2026. For Neil, we [music] had Rocket Lab and Nvidia. I talked about two healthcare names, Crystal Biotech and Billion. [music] Let us know your thoughts in the comments. What stocks are on your buy lists before the end of the year? Let us know. Hit the like and subscribe buttons and we will see you in the next video.

  3. 03 RKLB NASDAQ COMPRAR -26,18%
    Entrada $61,53 14 nov 2026
    Atual $45,42 20 nov 2026
    Resultado −$16,11
    vs. índice −17,6% SPY −8,6% no mesmo período
    Contexto da transcrição original
    … flow. So, it helps a business that is burning cash because it is developing rockets. And who knows, maybe the first Neutron Rocket launch is going to be successful. Maybe not. But it's definitely a business that still needs a lot of cash. I do think that the big big pullback that we've experienced in the recent months does give me a big a better opportunity to accumulate more shares. >> Yeah, I think that's right. a fascinating business to watch and um incredibly wellrun as well by Sir Peter Beck. With that, I want to talk about the next stock for today. Switching gears to a completely different industry. Got to talk a…

    I do think that the big big pullback that we've experienced in the recent months does give me a big a better opportunity to accumulate more shares.

    Contexto extraído por IA So, even with all the delays, even without launching one Neutron rocket, they managed to just increase the price to 70 million. and and that's the that's the story here. The backlog is not all an option. It's sort of real contracts, but they need to deliver. There's a lot of cost going into developing a rocket such as Neutron. So hopefully hopefully a year from now we will have already had a launch of Neutron. Hopefully that backlog also keeps on increasing. We will also have the complete acquisition of Idium which would make the whole rocket lab business more profitable. Redium is already generating free cash flow. So, it helps a business that is burning cash because it is developing rockets. And who knows, maybe the first Neutron Rocket launch is going to be successful. Maybe not. But it's definitely a business that still needs a lot of cash. I do think that the big big pullback that we've experienced in the recent months does give me a big a better opportunity to accumulate more shares. >> Yeah, I think that's right.

Transcrição Completa
Welcome back to the channel everyone. Today Neil and I are going to be talking about four stocks that we think look like great [music] buys before the end of 2026. Hard to believe that we're already getting down to the last couple months of [music] the year. There's a lot of businesses that I think we both have on our watch lists on our buy lists and we're going to be talking about some names across a few different industries right now. [music] A couple of these might be a little bit more unexpected. Excited to dive right in. Neil, good to see you today. >> Good to see you as well. And it is quite uh quite crazy that we are almost almost in 2027. So yeah, whoever is still uh wanted to sign up to the gym, something that you promised yourself in January may maybe January 2027, >> you have another chance. It's coming right around the corner. Uh but I'll I'll uh start off with my first one. My first one is a name that did report on Monday, November 9th, their quarterly figures, and that's Rocket Lab. Now, Rocket Lab is a company where I don't think looking at it from a purely valuation standpoint anybody's going to buy it because it's cheap. It's just less expensive. And it's also about what the company could look like 5 10 years down the line. Now they reported revenue up 73% year-over-year, 14.4% up sequentially. They of course they launch rockets. They have a launch business and they also have a a space systems business. That one was up 13% uh sequentially which is and it was around I think 80% of the overall revenue. All of that is is good and fine, but the real story is again about what happens in the future. Rocket Lab stock, I think we reached a peak of $150 this year. It's now trading in the low $50. So quite quite a rocket crash uh since the uh since the highs. But the reason why this has happened is not because of a rocket exploded. No, it's because one was super expensive, overvalued, and two, their next big rocket, which is Neutron, was supposed to have its first flight, let's say, at the end of this year, although I don't think that was realistic, and that was delayed yet again. It's been quite a couple of quarters, maybe a year or two of delays. The thing here is nice for 2027. We still don't know when in 2027 where it's going to be probably not Q1 but maybe Q2 maybe midway 2027. And the reason why Neutron is so important is because well whenever you launch a a Neutron rocket it costs way more than Electron. Electron is their really really small rocket and by the way they're soon going to be launching their 100th uh rocket which I think is the fastest company to to achieve that. But Neutron is very important to the long-term story of this business. Reusable rockets is very important. Capacity goes up quite a lot. More satellites go to space. The contracts get bigger and bigger. The launch contracts get of course more lucrative as well. This quarter they did tell us despite despite not launching one neutron rocket and despite many many delays we've seen total backlog increased by 52% sequentially not year-over-year sequentially to now $3.57 billion. They've signed 54 launches overall worth more than a billion dollar total. They've sold eight new Neutron launches for about $515 million, which they also told us that some of them have been priced at a higher um sale price of around $70 million, which I think the base price was 15 uh $55 million. So, even with all the delays, even without launching one Neutron rocket, they managed to just increase the price to 70 million. and and that's the that's the story here. The backlog is not all an option. It's sort of real contracts, but they need to deliver. There's a lot of cost going into developing a rocket such as Neutron. So hopefully hopefully a year from now we will have already had a launch of Neutron. Hopefully that backlog also keeps on increasing. We will also have the complete acquisition of Idium which would make the whole rocket lab business more profitable. Redium is already generating free cash flow. So, it helps a business that is burning cash because it is developing rockets. And who knows, maybe the first Neutron Rocket launch is going to be successful. Maybe not. But it's definitely a business that still needs a lot of cash. I do think that the big big pullback that we've experienced in the recent months does give me a big a better opportunity to accumulate more shares. >> Yeah, I think that's right. a fascinating business to watch and um incredibly wellrun as well by Sir Peter Beck. With that, I want to talk about the next stock for today. Switching gears to a completely different industry. Got to talk about healthcare. I'm going to talk about Crystal Biotech, ticker KR YS. So, Crystal Biotech, if you're not familiar, a little bit unusual in the world of growth biotech names. This is a commercial stage company. They already have an approved very profitable product. So this is not a a bet on a future clinical trial outcome. Uh Crystal Biotech's flagship drug is a therapy called VIVEC. It is the world's first topically applied atome gene therapy and it treats a condition known as uh distrophic epidermalisa or deeb. This is a very severe painful genetic skin disease. It causes horrible blistering and chronic wounds uh because of faulty collagen genes. And crystal biotech drug uses a modified a harmless version of the herpes virus to deliver a working copy of that gene right into a patient's own skin cells. So it's actually applied as a simple gel that a patient could use repeatedly at home. This isn't through a single, you know, one-time infusion. And that redossible delivery platform isn't just useful for this one rare disease. It's the foundation that Crystal Biotech is now extending to new programs where they are targeting other rare conditions of the lungs, the eyes, other rare skin disorders. So, it's really interesting, you know, how they built their platform around uh the herpes simplex virus. This is a a virus that has evolved over a long time to be good at two things, which is infecting skin cells and hiding from the body's immune system well enough to stay in a person for life without being permanently cleared. And so Crystal Biotech platform actually capitalizes on these two natural properties, but for a therapeutic purpose. Um, and that means that they are able to replace uh corrective copy of whatever gene a patient is missing, keep the virus's natural skill at slipping into skin cells without triggering any kind of a negative immune response within the patient. Now, just to put some numbers to how the company has been performing, they recently released their Q3 results in early November. Global revenue was $127 million. That was up 30% year-over-year. Their cumulative revenue since they launched Fijc is now at just over a billion dollars. Uh their gross margin is at 94%. They ended the quarter with about 1.2 billion in cash and investments. Now the stock has been under a little bit of pressure uh since they reported earnings. It actually dropped around 10% or more on the day of their earnings report. And that was primarily because management disclosed that they have a few a few key clinical data readouts for two of their key pipeline candidates have been pushed into 2027 rather than being released before the end of the year. So they have a uh therapeutic candidate that targets a rare eye condition. They are going to be reporting topline results from their ongoing clinical trials early next year. They have a cystic fibrosis therapy that has now uh been delayed the results until the first half of 2027. Says nothing about uh you know anything with regards to the business to be concerned about but just something to be aware of. You know Crystal Biotech has continued to expand internationally. They have uh of course expanded and launched within the US but they are done with pricing and reimbursement negotiations in markets like Germany and Italy. So, they're going to be launching uh within some of these markets as early as the beginning of 2027. Uh they're already benefiting from earlier European launches as well as expansion in Japan. And I'll also note that Crystal Biotech Board has authorized a $400 million share buyback program that's going to be executed over the next couple years. So, fascinating business, very much in the early stages of its growth. It has its one very profitable key flagship product, but they are rapidly expanding into other rare disease areas. It's a profitable business. It's a high margin one. Might be one to at least put on your watch list, if not your buy list, if you're interested in putting cash to work in biotech stocks. >> Very interesting name. I mean, the biotech segment of the market is one where it's either you're going to be very very successful or or it's a name where you probably won't hear about it a couple of years a couple of years down the line, but from what I I've just heard and and seen seems like a a pretty good company has also performed quite well uh this year and and over the past uh 12 months. So, pretty pretty good. Um my my next one is is a company that well how should I say over the last couple of years has completely changed changed the game in the in the stock market over the past couple of days has definitely changed something in uh in the news market and that's Nvidia. Now Nvidia we all know it I mean now it's not a $5 trillion company anymore. it has lost a little bit of it of its market cap over the past couple of days and weeks. Some of the reasons we know what's going on in the headlines right now with uh with the CEO, but I do want to talk about the business itself because the business is still a tremendous business. Yes, it's true that Jensen being the CEO, Jensen being Nvidia, Nvidia being Jensen, if let's say he were to step down, that could cause some pressure on the stock, would it would it be a thesis changer? I I doubt it because I do think that Nvidia has become a such a big company that that could be run by someone else. Of course, ideally Jensen does stay the company, but purely looking at the business today. I don't think that anything will change anytime soon. I still think they'll grow at least 70% uh next year. I still think that Google, Amazon, OpenAI, all of these uh companies are still going to buy Nvidia GPUs for for the foreseeable future. and and that represents right now a a a in my opinion a buying opportunity because valuation wise I think we're at 17 times forward earnings or or close to it of course generating an insane amount of free cash flow over the next couple of years will be generating well over half a trillion dollars in in free cash flow which is which is mindboggling so despite all of the headlines more recently whether it's around uh data center buildout AI high investments or now the new headlines that have popped up uh the the controversy around around the the CEO. I do think that the pressure of the stock does present long-term investors a a nice opportunity where the riskreward definitely favors the rewards or at least for me again because I do think that the AI buildout does continue. We spoke about cororewe in a in a previous video. Of course, Nvidia is an investor in Cororeef. Corre does buy a lot of Nvidia chips. Yes, we could say that Nvidia also backs Cororey, although two different terms maybe, but uh if Cororeef doesn't manage to to to sell X amount of chips, Nvidia will come in and and back them for at least I think $6 billion or so. Some might like these deals, some might not. That's completely fine. But Nvidia is is in a very good spot at the moment in this whole AI buildout. Stock is cheap. Business is growing. I mean the size of the business. This is now a four plus trillion dollar company generating tens of billions, hundreds of billions of dollars in revenue while still growing at least 70%. That's for next year. This year is going to be closer to 90% or so. very very profitable despite despite some of their biggest customers also becoming let's say rivals all designing their own custom silicon or the old custom chips working with Broadcom working with Marvel so yes there is a lot of com or AMD as well uh we've seen the Google TPU's uh announcement with uh with AMD I think on Monday so competition is increasing I do also think the momentum the market is just growing so much Nvidia's position very well very profitable company. Yes, unfortunately we do have some negative headlines affecting the stock. Could it affect the business? There's definitely a chance that it could affect the business where XYZ were to happen over the next couple of weeks. So, we'll see. But purely looking at valuation and business performance, I'd had to put uh this name right now on the list, especially since we are at the end of 2026 and I didn't think we would see an Nvidia trading at 17 times forward earnings by the end of this year. Yeah, I mean certainly the financial foundation of Nvidia, the business is you know running like a welloiled machine and the tailwinds that are driving the business forward just broadly those secular tailwinds are not going to go anywhere regardless of what happens with you know the story that we're seeing around the CEO in the coming weeks and months. Who knows if we will see a leadership change or not, but uh and that may in fact be you know necessary and that may shake the stock up and you know we will see. We don't want to speculate about what's going to happen. Um but certainly the core underlying business uh is one that I think remains deeply tethered to the AI buildout that's arguably one of the most recognizable names in the space. Um and probably has one of the strongest financial foundations of any of the AI companies uh that we talk about. Um, for the final stock in today's video, I'm going to talk about another healthcare name. Another one that's probably a bit less known. Trying to shake it up a little bit. You know, we see in the comments sometimes that you guys uh mention that we only talk about tech stocks. So, I'm trying to shake things up a bit. We'll see. Uh, so Billionto One, uh, ticker B LLN. If you're not familiar with Billion to One, this is certainly not a household name. They are a molecular diagnostics company. So their platform is built around a kind of proprietary technology that it calls quantitating quantitative counting templates or QCT. This is essentially a platform that can detect and measure uh genetic material with a level of sensitivity that the legacy diagnostic companies generally can't match. And Billionto one applies that technology across a couple different product lines. The first and currently its flagship business is prenatal testing. uh they have the first and only non-invasive prenatal tests uh for red blood cell and platelet fetal antigens in the US. The second is their oncology business and they are currently building out a an entire family of liquid biopsy tests that can detect and monitor cancer from a simple blood draw rather than requiring an invasive tissue biopsy. And the oncology business is the one that I'm most excited about that I think will be most important to the business and its growth story moving forward. So one of the things that's interesting uh talking about the the platform technology that billion to one runs on um just to explain why it's a bit more differentiated. So when you draw blood from a pregnant woman there's a t tiny amount of fetal DNA that's floating freely in her bloodstream and that's mixed in with a much larger amount of her DNA. So pulling a faint specific fetal signal out of that much larger background of DNA is sort of the central challenge of non-invasive prenatal testing. That same kind of basic core challenge also shows up in cancer testing. So for example, after a tumor is removed, there might only be a handful of cancer DNA fragments floating among millions of healthy ones. And so finding those few fragments is what minimal residual disease testing is actually trying to do. billion to one's platform attaches a unique tag to each individual DNA molecule. So they can actually count those molecules rather than estimate their proportion. You could sort of think of it of as the difference between weighing a mixed bag of coins to estimate how many quarters are in it versus tagging and counting each coin at a time. And that precision, that single molecule level precision is what allows billion to one to offer these very accurate diagnostic tests that so far some of the more established competitors have not. Um, and this is showing up in the numbers as well. So they reported also about a week ago their third quarter results. Total revenue uh beat uh consensus estimates was up about 50% year-over-year. saluted earnings per share was more than double what Wall Street was expecting. Their prenatal revenue was up 41% year-over-year. Their oncology revenue, which is still a smaller, but the fastest growing part of the business, was up 96% year-over-year, is now running at an annualized rate of about 68 million. They generated about $9 million in free cash flow in the quarter. It was their fifth consecutive quarter of positive GAP operating income. They have about 562 million in cash and cash equivalents on their balance sheet. One of the biggest things to watch as it pertains to the oncology business, they have a new test that they are launching in mid December. This is a a test for minimal residual disease. Basically, it's designed to detect the microscopic traces of cancer left behind after a patient's tumor has already been surgically removed. It's a blood only test. It is available for all solid tumors. Was day one. um and they're going to be uh launching this again here in the next few weeks. And so this is uh key as they are growing out their cohort of oncology tests. It it's a fascinating business. It's a profitable one. It's one that's continuing to see really solid growth across both their prenatal natal testing and oncology businesses. Uh but to me the fact that they are launching these really differentiated cancer monitoring products into uh a vast addressable market management uh estimates that that market is worth about $30 billion on top of this already validated technology platform. I think there's a long way for billion to want u to run and I think this is certainly a business to at least put on your watch list before the end of 2026. It's certainly a very cool name. >> Billion to one. It's very catchy. >> Yeah. >> Okay, everyone. That's [music] four stocks that Neil and I would consider buying before the end of 2026. For Neil, we [music] had Rocket Lab and Nvidia. I talked about two healthcare names, Crystal Biotech and Billion. [music] Let us know your thoughts in the comments. What stocks are on your buy lists before the end of the year? Let us know. Hit the like and subscribe buttons and we will see you in the next video.

Comentários 0

Ainda não há comentários. Seja o primeiro a compartilhar sua opinião!